文献速递妇科生殖医学

针对早发性子宫内膜异位症和子宫腺肌症、以新进化论为导向的二级预防提案。第二部分:药物干预

Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions.
PubMed 文献 · Hum Reprod · 2024-01-01

基于流行病学数据,子宫内膜异位症发病曲线在25岁左右急剧上升,青少年诊断延迟常超过10年。排卵和月经是炎症事件,反复痛经可能促进中枢敏化和慢性疼痛。二级预防应聚焦严重症状青少年,长期排卵抑制可用至备孕,需评估药物安全性。

要点

  • 青少年诊断延迟常超过10年,早发性子宫内膜异位症和子宫腺肌症应及早怀疑。
  • 长期排卵抑制可用于严重症状青少年直至备孕,药物安全性评估至关重要。
  • 腹腔镜应保留给拒绝激素治疗或一线药物无效、不耐受或禁忌的青少年。

核心结论

  • 二级预防应聚焦于能从干预中获益最大的年龄组,即严重症状的青少年,以减轻痛苦、限制病变进展并保护未来生殖潜能。

研究设计与样本

  • 本文为提案性综述,基于流行病学数据和机制推理提出药物干预策略。

主要发现

  • 子宫内膜异位症发病曲线在25岁左右急剧上升,成人诊断延迟通常为5至8年,青少年则超过10年。
  • 排卵和月经是炎症事件,反复发生可能理论上促进子宫内膜异位症和子宫腺肌症的早期发展。
  • 月经初潮后反复急性痛经可能不仅是 ensuing 子宫内膜异位症或子宫腺肌症的指标,还可能通过中枢敏化机制促进急性向慢性盆腔痛的转变。

关键数值与推荐

  • 对于无公认雌激素主要禁忌症的青少年,使用极低剂量复方口服避孕药与血栓栓塞事件个体绝对风险的边际增加相关。
  • 含雌二醇而非炔雌醇的口服避孕药可能进一步限制血栓栓塞风险。
  • 口服、皮下和肌内孕激素不增加血栓栓塞风险,但可能干扰年轻女性达到峰值骨量。
  • 左炔诺孕酮释放宫内装置可能是青少年的安全替代选择,因常诱导闭经而不抑制卵巢活动。
  • 关于肿瘤风险,长期使用雌激素-孕激素组合的净效应是总体癌症风险的小幅降低。

临床怎么用

  • 对于有严重症状的青少年,即使体格检查和超声发现阴性,也应及早怀疑早发性子宫内膜异位症和子宫腺肌症。
  • 可建立长期排卵抑制直至备孕。
  • 腹腔镜应保留给拒绝激素治疗或一线药物无效、不耐受或禁忌的青少年。
  • 提出了针对临床怀疑早发性子宫内膜异位症或子宫腺肌症年轻个体的诊断和治疗算法,包括自我报告的结果测量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

According to consistent epidemiological data, the slope of the incidence curve of endometriosis rises rapidly and sharply around the age of 25 years. The delay in diagnosis is generally reported to be between 5 and 8 years in adult women, but it appears to be over 10 years in adolescents. If this is true, the actual onset of endometriosis in many young women would be chronologically placed in the early postmenarchal years. Ovulation and menstruation are inflammatory events that, when occurring repeatedly for years, may theoretically favour the early development of endometriosis and adenomyosis. Moreover, repeated acute dysmenorrhoea episodes after menarche may not only be an indicator of ensuing endometriosis or adenomyosis, but may also promote the transition from acute to chronic pelvic pain through central sensitization mechanisms, as well as the onset of chronic overlapping pain conditions. Therefore, secondary prevention aimed at reducing suffering, limiting lesion progression, and preserving future reproductive potential should be focused on the age group that could benefit most from the intervention, i.e. severely symptomatic adolescents. Early-onset endometriosis and adenomyosis should be promptly suspected even when physical and ultrasound findings are negative, and long-term ovulatory suppression may be established until conception seeking. As nowadays this could mean using hormonal therapies for several years, drug safety evaluation is crucial. In adolescents without recognized major contraindications to oestrogens, the use of very low-dose combined oral contraceptives is associated with a marginal increase in the individual absolute risk of thromboembolic events. Oral contraceptives containing oestradiol instead of ethinyl oestradiol may further limit such risk. Oral, subcutaneous, and intramuscular progestogens do not increase the thromboembolic risk, but may interfere with attainment of peak bone mass in young women. Levonorgestrel-releasing intra-uterine devices may be a safe alternative for adolescents, as amenorrhoea is frequently induced without suppression of the ovarian activity. With regard to oncological risk, the net effect of long-term oestrogen-progestogen combinations use is a small reduction in overall cancer risk. Whether surgery should be considered the first-line approach in young women with chronic pelvic pain symptoms seems questionable. Especially when large endometriomas or infiltrating lesions are not detected at pelvic imaging, laparoscopy should be reserved to adolescents who refuse hormonal treatments or in whom first-line medications are not effective, not tolerated, or contraindicated. Diagnostic and therapeutic algorithms, including self-reported outcome measures, for young individuals with a clinical suspicion of early-onset endometriosis or adenomyosis are proposed.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vercellini P, Bandini V, Viganò P, et al. Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions. Hum Reprod. 2024. PMID: 37951241. doi:10.1093/humrep/dead206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。